With IPO mon­ey, Neumo­ra eyes deals as CEO brings M&A chops from roles at Ab­b­Vie, JP Mor­gan

Neumo­ra Ther­a­peu­tics, a brain dis­ease biotech born out of stitch­ing to­geth­er mul­ti­ple neu­ro­science star­tups, is look­ing to repli­cate its orig­i­nal play­book by com­ple­ment­ing its sev­en-drug pipeline with ex­ter­nal as­sets thanks to a Sep­tem­ber IPO and $520 mil­lion bal­ance sheet.

The drug­mak­er al­ready has its hands full with a trio of Phase III stud­ies in ma­jor de­pres­sive dis­or­der; mul­ti­ple clin­i­cal tri­als be­ing pre­pared for bipo­lar de­pres­sion, schiz­o­phre­nia and Alzheimer’s dis­ease ag­i­ta­tion next year; and an IND planned in ALS in the back half of 2024. But with run­way in­to 2026, Neumo­ra sees room for more.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER